Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery (PREVENT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03216187|
Recruitment Status : Recruiting
First Posted : July 13, 2017
Last Update Posted : October 27, 2021
|Condition or disease||Intervention/treatment||Phase|
|Persistent Postoperative Pain||Drug: Pregabalin Drug: Placebos||Phase 3|
BACKGROUND Persistent postsurgical pain occurs in more than 30% of patients undergoing breast cancer surgery. Evidence that gabapentinoids such as pregabalin may reduce the incidence of persistent postsurgical pain is ambiguous, potentially because in previous trials prophylactic treatment was administered to every patient undergoing surgery. The patients at low risk of long term pain, were exposed to side effects without much benefit to expect.
AIM Validating or refuting the utility of pregabalin to prevent long term post-operative pain in patients at high risk of persistent pain after breast cancer surgery.
METHODS Randomized, double-blind, placebo-controlled trial of pregabalin (2*150mg from the day before breast cancer surgery until 2 weeks after surgery) in patients at high risk of persistent pain (>30%). High-risk patients are identified by a risk score derived from a previous observational study. The main outcome is the incidence of clinically important pain (necessitating analgesic treatment, or having an intensity of >3 at rest or >5 on movement) at 3 months after surgery. Secondary outcomes are: incidence of neuropathic pain, pain interference, and incidences at 6 and 12 months of follow-up. In addition, side effects of pregabalin and the retention rate during the treatment period will be monitored, as well as patient expectancies.
RELEVANCE This is the first study for prevention of persistent postoperative pain which targets only high-risk patients, thus lowering a false negative outcome and averting the risk of side effects for patients at low risk.
The study is powered to show a reduction of the incidence of clinically important pain at 3 months of 20%. In the case the study shows that this can be achieved and pregabalin is well tolerated, the preventive use of pregabalin for breast cancer surgery would be justified at least in high-risk patients. On the other hand, a negative result would indicate the futility of pregabalin prevention, which is already in routine use in many hospitals.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||double-blinded, randomized, placebo-controlled trial|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||study drugs (including identical placebos) and randomisation lists are prepared by the hospital pharmacy and are kept secret from the investigators until the end of the study and the "freezing" of the electronic data base|
|Official Title:||Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery|
|Actual Study Start Date :||January 9, 2018|
|Estimated Primary Completion Date :||January 1, 2023|
|Estimated Study Completion Date :||January 1, 2024|
Pregabalin 150 mg twice daily, starting from the evening before surgery, continuing with two times 150mg per day for 12 days, and ending with one 150mg capsule every evening for the final 3 days.
pregabalin 150 mg capsules
Other Name: Pregabalin 150mg capsules
Placebo Comparator: Placebo
Identical placebo capsules twice daily, starting from the evening before surgery, continuing with two capsules per day for 12 days, and ending with one capsule every evening for the final 3 days.
capsules identical to pregabalin but without active drug
Other Name: placebo capsules
- incidence of "clinically important pain" at 3 months after surgery [ Time Frame: 3 months ]"Clinically important pain" is defined by: taking analgesics for pain at the surgical site OR average resting pain at the surgical site >3/10 OR average movement-induced pain at the surgical site >5/10.
- Pregabalin-related side effects [ Time Frame: 10 days ]blurred vision or diplopia, somnolence or sleepiness, abnormal thinking, confusional state, disturbed attention, and falls, as well as the effects noted in the "generic assessment of side effects" GASE questionnaire
- retention rates of pregabalin treatment [ Time Frame: 30 days ]
- acute pain intensity and patient-reported pain outcome at 24h [ Time Frame: 24 hours ]PAIN-OUT questionnaire
- pain intensity at rest and movement, pain interference [ Time Frame: 3, 6, and 12 months ]Brief Pain Inventory, BPI
- neuropathic pain [ Time Frame: 3, 6, and 12 months ]incidence of neuropathic pain defined as a DN4-self-evaluation score ≥4
- patient-reported relevance of pain [ Time Frame: 3, 6, and 12 months ]response to the question: "do you consider your pain as significant?"
- Patient-reported acceptance of the preventive treatment [ Time Frame: 3 months ]response to the question "In retrospect, do you consider the preventive treatment worthwhile, given your pain outcome and your experience of taking the medication?")
- Expectations about treatment benefits before treatment and after [ Time Frame: 10 days ]responses to the questions: "How much pain do you expect 3 months from now?"" "How efficient do you think the study treatment is against the long-term pain (i.e. what is the success rate in %)?" "How well do you think it will work for you? (i.e. reduction in pain score 0-10)". Beliefs about treatment attribution after 10 days of treatment (question: "Do you think that you received the real drug or the placebo?")
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03216187
|Contact: Benno Rehberg-Klug, MD||+4179 55 firstname.lastname@example.org|
|Contact: Stanislas Mathivon, MSemail@example.com|
|Bern, Switzerland, 3010|
|Contact: Ulrike Stamer, MD +41 31 632 99 95 firstname.lastname@example.org|
|Principal Investigator: Ulrike Stamer, MD|
|Contact: Patrizia Sager, MD|
|Principal Investigator: Patrizia Sager, MD|
|Hôpitaux Universitaires de Genève HUG||Recruiting|
|Geneva, Switzerland, 1211|
|Contact: Domitille Dereu, MD +41795532086 email@example.com|
|Principal Investigator: Domitille Dereu, MD|
|Sub-Investigator: Georges Savoldelli, MD|
|Clinique des Grangettes||Recruiting|
|Contact: Delphine Bachmann|
|Principal Investigator: Sindy Monnier, MD|
|Clinique de Genolier||Recruiting|
|Genolier, Switzerland, 1272|
|Contact: Magdalena Kohlik, MD|
|Principal Investigator: Magdalena Kohlik, MD|
|Centre Hospitalier Universitaire Vaudois CHUV||Recruiting|
|Lausanne, Switzerland, 1011|
|Contact: Marc Suter, MD + 41 (0)79 556 3479 Marc.Suter@chuv.ch|
|Sub-Investigator: Chantal Berna-Renella, MD|
|Sub-Investigator: Moira Baeriswyl, MD|
|Principal Investigator: Marc Suter, MD|
|Study Director:||Benno Rehberg-Klug, MD||HUG|
|Study Director:||Marc Suter, MD||CHUV|
|Study Director:||Ulrike Stamer, MD||Inselspital|